Summary
In patients with active cancer and acute venous thromboembolism, tinzaparin reduced the cumulative risk of recurrent venous thromboembolism and significantly reduced the risk of symptomatic deep vein thrombosis. Full-dose tinzaparin did not increase the risk of major bleeding and was associated with a significantly decreased risk of clinically relevant nonmajor bleeding.
- recurrent venous thromboembolism
- oncology
- prevention
- tinzaparin
- warfarin
- Long-Term Tinzaparin Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
- NCT01130025
- © 2014 SAGE Publications
Tools
Tinzaparin Reduces the Risk of Recurrent Thromboembolic Events in Patients With Cancer
Permalink:
Table of contents
Cited By...
- No citing articles found.